CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease - Top-Institutions - MDSpire

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial

  • April 13, 2026

  • 2 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Hematology
    • Gene Therapy
    • Pediatric Hematology-Oncology

  • #2

    National Institutes of Health (NIH) / National Heart, Lung, and Blood Institute (NHLBI)
    National Institutes of Health (NIH) / National Heart, Lung, and Blood Institute (NHLBI)

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Gene Therapy
    • Clinical Research

  • #3

    Boston Children’s Hospital / Dana-Farber Cancer Institute / Harvard Medical School
    Boston Children’s Hospital / Dana-Farber Cancer Institute / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Pediatric Hematology
    • Gene Therapy
    • Stem Cell Transplantation

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Gene Editing
    • Stem Cell Transplantation

  • #5

    St. Jude Children’s Research Hospital
    St. Jude Children’s Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Hematology-Oncology
    • Gene Therapy
    • Stem Cell Transplantation

Original Source(s)

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

  • April 13, 2026

Related Content

Early detection and correction of preoperative anemia in patients undergoing colorectal surgery—a prospective study

Patient Resource on Vascular Disorders: Understanding Hereditary Hemorrhagic Telangiectasia (HHT)

Peri-Operative Blood Transfusion Does Not Influence Overall and Disease-Free Survival After Radical Gastrectomy for Stage II/III Gastric Cancer: a Propensity Score Matching Analysis